| Trial ID: | L3451 |
| Source ID: | NCT00957060
|
| Associated Drug: |
Glimepiride (Hoe490)
|
| Title: |
Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients
|
| Acronym: |
SUMER
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GLIMEPIRIDE (HOE490)|DRUG: SITAGLIPTIN
|
| Outcome Measures: |
Primary: HbA1c, at baseline, week 12 and week 24|Fasting and postprandial glucose, at baseline, week 2, 4, 12 and 24 |
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
400
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-07
|
| Completion Date: |
2010-10
|
| Results First Posted: |
|
| Last Update Posted: |
2010-11-30
|
| Locations: |
Sanofi-Aventis Administrative Office, Guatemala City, Guatemala|Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico
|
| URL: |
https://clinicaltrials.gov/show/NCT00957060
|
